Upper Gastrointestinal Safety with the Buffered Solution of Alendronate 70mg: Postmarketing Experience.

被引：0
|
作者：
Hruska, Josef [1 ]
Jorgensen, Flemming Kjaer [2 ]
Eriksen, Erik Fink [3 ]
机构：
[1] MeDACom GmbH, Bern, Switzerland
[2] KLIFO AS, Glostrup, Denmark
[3] Oslo Univ Hosp, Oslo, Norway
来源：
JOURNAL OF BONE AND MINERAL RESEARCH | 2017年 / 32卷
关键词：
OSTEOPOROSIS;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SU0292
引用
收藏
页码：S269 / S269
页数：1
相关论文
共 50 条
  • [41] Safety and tolerability of once-weekly alendronate 70 mg is comparable to that of placebo in men and women with periodontal disease.
    Genco, R
    Adams, D
    Jeffcoat, M
    Klokkevold, P
    Page, R
    Cizza, G
    Kimberlin, M
    Lombardi, A
    Meng, L
    Santora, A
    Shih, W
    JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 : S489 - S489
  • [42] Efficacy, Side Effects, Safety and Effects on Bone Turnover Markers of once a Week Sandoz Alendronate Sodium Trihydrate 70 mg
    Waikakul, S.
    Sintuvanich, N.
    Assanasuwan, T.
    Soparat, K.
    MALAYSIAN ORTHOPAEDIC JOURNAL, 2011, 5 (02) : 15 - 19
  • [43] The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: A placebo-controlled endoscopy study
    Lanza, F
    Sahba, B
    Schwartz, H
    Winograd, S
    Torosis, J
    Quan, H
    Reyes, R
    Musliner, T
    Daifotis, A
    Leung, A
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2002, 97 (01): : 58 - 64
  • [44] Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget's disease
    Hooper, M.
    Faustino, A.
    Reid, I. R.
    Hosking, D.
    Gilchrist, N. L.
    Selby, P.
    Wu, M.
    Salzmann, G.
    West, J.
    Leung, A.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 (01) : 141 - 150
  • [45] Randomized, active-controlled study of once-weekly alendronate 280 mg high dose oral buffered solution for treatment of Paget’s disease
    M. Hooper
    A. Faustino
    I. R. Reid
    D. Hosking
    N. L. Gilchrist
    P. Selby
    M. Wu
    G. Salzmann
    J. West
    A. Leung
    Osteoporosis International, 2009, 20 : 141 - 150
  • [46] Upper Gastrointestinal Tract Transit Times of Tablet and Drinkable Solution Formulations of Alendronate: A Bioequivalence and a Quantitative, Randomized Study using Video Deglutition
    Claudia Gómez Acotto
    Carlos Antonelli
    Damien Flynn
    Dennis McDaid
    Emilio J. A. Roldán
    Calcified Tissue International, 2012, 91 : 325 - 334
  • [47] Upper Gastrointestinal Tract Transit Times of Tablet and Drinkable Solution Formulations of Alendronate: A Bioequivalence and a Quantitative, Randomized Study using Video Deglutition
    Gomez Acotto, Claudia
    Antonelli, Carlos
    Flynn, Damien
    McDaid, Dennis
    Roldan, Emilio J. A.
    CALCIFIED TISSUE INTERNATIONAL, 2012, 91 (05) : 325 - 334
  • [48] A randomised, active-controlled, 6-month study of once weekly 280 mg oral buffered alendronate solution for treatment of Paget's disease of bone
    Hooper, M. J.
    Faustino, A.
    Reed, I. R.
    Hosking, D.
    Gilcrest, N.
    Selby, P.
    Wu, M.
    Salzmann, G.
    West, J.
    Leung, A.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S220 - S220
  • [49] Early clinical experience of the safety and efficacy of EndoClot in the management of non-variceal upper gastrointestinal bleeding
    Beg, Sabina
    Al-Bakir, Ibrahim
    Bhuva, Meha
    Patel, Jay
    Fullard, Mark
    Leahy, Anthony
    ENDOSCOPY INTERNATIONAL OPEN, 2015, 3 (06) : E605 - E609
  • [50] EFFICACY AND SAFETY OF FULL THICKNESS RESECTION (FTR) IN THE UPPER GASTROINTESTINAL TRACT (UGIT): A SINGLE CENTER NORTH AMERICAN EXPERIENCE
    Al-Taee, Ahmad
    Vareedayah, Ashley A.
    Gross, Samantha
    Yuen, Poi Yu Sofia
    Cohen, Jonathan
    Khanna, Lauren
    Haber, Gregory B.
    GASTROINTESTINAL ENDOSCOPY, 2022, 95 (06) : AB226 - AB226
12345